Department of Cardiovascular Biology and Medicine, Juntendo University Graduate School of Medicine, 2-1-1 Hongo, Bunkyo-ku, Tokyo, 113-0033, Japan.
Japan Agency for Medical Research and Development-Core Research for Evolutionary Medical Science and Technology (AMED-CREST), Japan Agency for Medical Research and Development, Tokyo, Japan.
Heart Vessels. 2021 Aug;36(8):1117-1124. doi: 10.1007/s00380-021-01794-2. Epub 2021 Feb 19.
Chronic kidney disease (CKD) and anemia are each individually associated with worse clinical outcomes in patients with coronary artery disease (CAD). However, the prognostic impact of both CKD and anemia on clinical outcomes, when they coexist, remains unclear in CAD patients after percutaneous coronary intervention (PCI). We studied 2484 CAD patients who underwent their first PCI and had available date on preprocedural hemoglobin between 2000 and 2016. The patients were divided into four groups according to the presence of CKD and/or anemia. We evaluated the incidences of all-cause death and major adverse cardiac and cerebrovascular events (MACCEs), including cardiovascular death, non-fatal myocardial infarction, and stroke. Among the patients, 310 patients (12.5%) had both CKD and anemia (CKD with anemia group), 309 (12.4%) had CKD only, 461(18.6%) had anemia only, and 1404 (56.5%) had neither CKD nor anemia. Patients in the CKD with anemia group were older and had a higher incidence of hypertension and diabetes mellitus. During a median follow-up period of 3.7 years, Kaplan-Meier curves showed that patients in the CKD with anemia group had significantly higher incidences of MACCE and all-cause death than the CKD only and anemia only group (both log-rank p < 0.001). Using patients with the no CKD or anemia group as a reference, the adjusted hazard ratios (HRs), 95% confidence interval for MACCE were 1.51 (0.92-2.47) for the CKD only, 1.48 (0.94-2.32) for the anemia only and 2.00 (1.18-3.38) for the CKD with anemia group. Moreover, the adjusted HR for all-cause death were 1.42 (0.96-2.10) for the CKD only, 1.79 (1.28-2.51) for the anemia only, and 1.92 (1.30-2.84) for the CKD with anemia group. In conclusion, the combined effects of both CKD and anemia on outcomes after PCI were worse than either of their individual effects.
慢性肾脏病(CKD)和贫血单独与冠状动脉疾病(CAD)患者的临床结局恶化相关。然而,在经皮冠状动脉介入治疗(PCI)后,CKD 和贫血共存对 CAD 患者的临床结局的预后影响尚不清楚。我们研究了 2484 名接受首次 PCI 且 2000 年至 2016 年期间有术前血红蛋白数据的 CAD 患者。根据是否存在 CKD 和/或贫血,将患者分为四组。我们评估了全因死亡和主要不良心脏和脑血管事件(MACCE)的发生率,包括心血管死亡、非致死性心肌梗死和中风。在患者中,310 名患者(12.5%)同时存在 CKD 和贫血(CKD 伴贫血组),309 名(12.4%)仅存在 CKD,461 名(18.6%)仅存在贫血,1404 名(56.5%)既没有 CKD 也没有贫血。CKD 伴贫血组患者年龄较大,且高血压和糖尿病的发生率较高。在中位随访 3.7 年期间,Kaplan-Meier 曲线显示 CKD 伴贫血组的 MACCE 和全因死亡发生率明显高于仅 CKD 组和仅贫血组(均 log-rank p < 0.001)。以无 CKD 或无贫血组为参考,MACCE 的调整后风险比(HR),95%置信区间为仅 CKD 组 1.51(0.92-2.47),仅贫血组 1.48(0.94-2.32),CKD 伴贫血组 2.00(1.18-3.38)。此外,仅 CKD 组全因死亡的调整 HR 为 1.42(0.96-2.10),仅贫血组为 1.79(1.28-2.51),CKD 伴贫血组为 1.92(1.30-2.84)。总之,CKD 和贫血对 PCI 后结局的联合影响比各自的影响更差。